Research ArticleCORONAVIRUS

IgA dominates the early neutralizing antibody response to SARS-CoV-2

See allHide authors and affiliations

Science Translational Medicine  20 Jan 2021:
Vol. 13, Issue 577, eabd2223
DOI: 10.1126/scitranslmed.abd2223

stm.sciencemag.org/cgi/content/full/13/577/eabd2223/DC1

Fig. S1 (related to Fig. 1). Intracellular antibody expression in circulating plasmablasts.

Fig. S2 (related to Fig. 1). Circulating TFH cells in blood of SARS-CoV-2-infected patients.

Fig. S3 (related to Fig. 2). Reproducibility of photonic ring immunoassay to detect anti-RBD and anti-NC antibodies.

Fig. S4 (related to Fig. 2). Early detection of anti-RBD antibodies in serum from SARS-CoV-2-infected patients.

Fig. S5 (related to Fig. 3). Neutralizing activity of serum, BAL, and saliva from SARS-CoV-2-infected patients.

Table S1. Demographics, baseline characteristics, treatment, and outcome of 38 COVID-19 assessed for blood plasmablasts.

Table S2. Demographics and baseline characteristics of COVID-19 patients.

Table S3. Clinical characteristics, laboratory results, treatment, and outcome of COVID-19 patients.

Table S4. Virus-specific IgG, IgM, and IgA titers according to the clinical course of the disease in COVID-19 patients.

Table S5. Demographics, baseline characteristics, treatment, and outcome of patients with acute respiratory distress syndrome during the course of COVID-19.

Table S6. Human antibodies used for B and T cell phenotyping.

Data file S1. Raw data spreadsheet.